Geode Capital Management LLC Raises Stock Position in Tempus AI, Inc. (NASDAQ:TEM)

Geode Capital Management LLC lifted its position in Tempus AI, Inc. (NASDAQ:TEM) by 0.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 133,171 shares of the company’s stock after purchasing an additional 539 shares during the period. Geode Capital Management LLC owned 0.09% of Tempus AI worth $7,537,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of TEM. Pier Capital LLC bought a new position in shares of Tempus AI during the 2nd quarter worth $2,301,000. Federated Hermes Inc. bought a new position in Tempus AI during the 2nd quarter worth about $19,886,000. Revolution Growth Management Company Inc. purchased a new position in Tempus AI during the 2nd quarter valued at about $128,133,000. Allen Operations LLC bought a new stake in shares of Tempus AI in the 2nd quarter valued at about $3,831,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Tempus AI in the 2nd quarter worth approximately $634,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Wolfe Research started coverage on shares of Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Piper Sandler reissued a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Bank of America boosted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, December 13th. Finally, Loop Capital raised their price target on shares of Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a report on Tuesday, October 15th. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Tempus AI has an average rating of “Moderate Buy” and an average price target of $56.00.

Insider Activity

In other news, Director David R. Epstein sold 620 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total value of $25,922.20. Following the completion of the transaction, the director now directly owns 27,894 shares in the company, valued at $1,166,248.14. This trade represents a 2.17 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total transaction of $16,999,610.00. Following the completion of the transaction, the insider now owns 16,164,449 shares in the company, valued at approximately $694,263,084.55. This trade represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 845,041 shares of company stock valued at $35,125,473 over the last ninety days.

Tempus AI Trading Up 1.5 %

Shares of Tempus AI stock opened at $34.25 on Friday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The firm’s 50 day simple moving average is $49.04 and its two-hundred day simple moving average is $46.62.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.